Somatostatin receptors (sstrs) are G-protein coupled receptors that modulate hormone secretions. Their overexpression on neuroendocrine tumours (NETs) has enabled successful imaging of these cancers with radioactive peptides using positron emission tomography. Luminal A breast cancers also overexpress sstr, but with a lower and more heterogeneous density than NETs. Recently, several authors demonstrated higher tumour binding with sstr antagonists compared to agonists. Antagonists are hypothesized to bind to target receptors in multiple configurations, thus labeling more binding sites than high-affinity agonists. This property could result in better visualization of tumours with lower sstr density, such as breast cancers. We hypothesized th...
A variety of radiolabeled somatostatin analogs have been developed for targeting of somatostatin rec...
Neuroendocrine tumours (NETs) are a heterogeneous group with significant variation in morphological ...
The aim of this review is to summarize the developments and briefly characterize the somatostatin an...
Somatostatin receptors (sstrs) are G-protein coupled receptors that modulate hormone secretions. The...
Background: The somatostatin receptor subtype 2 (sstr2) is expressed on a majority ...
Targeting neuroendocrine tumors expressing somatostatin receptor subtypes (sst) with radiolabeled so...
International audienceIdentified in 1973, somatostatin (SST) is a cyclic hormone peptide with a shor...
Preclinical and clinical studies have indicated that somatostatin receptor (sst)-expressing tumors d...
PURPOSE: Somatostatin receptor (sst) targeting is an established method to image and treat sst-posit...
Purpose: Targeting of tumours positive for somatostatin receptors (sst) with radiolabelled peptides ...
Introduction: Interest in SST-analogue-based treatments is increasing, largely because of the succes...
Radiolabeled sst 2 and sst 3 antagonists are better candidates for tumor targeting than agonists wit...
SummaryThe prototypes for tumor targeting with radiolabeled peptides are derivatives of somatostatin...
Purpose: Peptide receptor targeting has become an increasingly attractive method to target tumors di...
Neuroendocrine tumors (NETs) are characterized by cellular overexpression of somatostatin receptors ...
A variety of radiolabeled somatostatin analogs have been developed for targeting of somatostatin rec...
Neuroendocrine tumours (NETs) are a heterogeneous group with significant variation in morphological ...
The aim of this review is to summarize the developments and briefly characterize the somatostatin an...
Somatostatin receptors (sstrs) are G-protein coupled receptors that modulate hormone secretions. The...
Background: The somatostatin receptor subtype 2 (sstr2) is expressed on a majority ...
Targeting neuroendocrine tumors expressing somatostatin receptor subtypes (sst) with radiolabeled so...
International audienceIdentified in 1973, somatostatin (SST) is a cyclic hormone peptide with a shor...
Preclinical and clinical studies have indicated that somatostatin receptor (sst)-expressing tumors d...
PURPOSE: Somatostatin receptor (sst) targeting is an established method to image and treat sst-posit...
Purpose: Targeting of tumours positive for somatostatin receptors (sst) with radiolabelled peptides ...
Introduction: Interest in SST-analogue-based treatments is increasing, largely because of the succes...
Radiolabeled sst 2 and sst 3 antagonists are better candidates for tumor targeting than agonists wit...
SummaryThe prototypes for tumor targeting with radiolabeled peptides are derivatives of somatostatin...
Purpose: Peptide receptor targeting has become an increasingly attractive method to target tumors di...
Neuroendocrine tumors (NETs) are characterized by cellular overexpression of somatostatin receptors ...
A variety of radiolabeled somatostatin analogs have been developed for targeting of somatostatin rec...
Neuroendocrine tumours (NETs) are a heterogeneous group with significant variation in morphological ...
The aim of this review is to summarize the developments and briefly characterize the somatostatin an...